Page 2 - Zhu Yidong News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Zhu yidong. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Zhu Yidong Today - Breaking & Trending Today

Biomedical industry a new 'growth engine' in China


Biomedical industry a new growth engine in China
1
2020-12-28 15:22:20Xinhua
Editor : Li Yan
ECNS App Download
In the Jinan-based Qilu Pharmaceutical Group Co., Ltd plant located in east China s Shandong Province, production of China s first bevacizumab injection is running full steam ahead.
The drug, which is mainly used to treat advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer, broke the exclusive monopoly of foreign pharmaceutical giants on similar drugs in China after it entered the market late last year.
As a leading enterprise in China s pharmaceutical industry, Qilu Pharmaceutical realized a sales revenue of 23 billion yuan (about 3.5 billion U.S. dollars) last year. Meanwhile, the company exported 615 million U.S. dollars of products, up 14 percent year on year. ....

United States , Zhao Yan , Zhu Yidong , Li Yan , Qilu Institute Of Innovative Pharmaceutical Research , China Pharmaceutical Enterprises Association , Qilu Pharmaceutical Group Co Ltd , Chinese Foreign Ministry , Shandong Province , Qilu Pharmaceutical , Qilu Institute , Innovative Pharmaceutical , Jiangsu Province , Tan Yong , China Pharmaceutical Enterprises , ஒன்றுபட்டது மாநிலங்களில் , ழோ யான் , லி யான் , சீனா மருந்து நிறுவனங்கள் சங்கம் , சீன வெளிநாட்டு அமைச்சகம் , சாண்டோங் மாகாணம் , புதுமையானது மருந்து , பழுப்பு யோங் , சீனா மருந்து நிறுவனங்கள் ,

Biomedical industry a new "growth engine" in China--China Economic Net


In the Jinan-based Qilu Pharmaceutical Group Co., Ltd plant located in east China s Shandong Province, production of China s first bevacizumab injection is running full steam ahead.
The drug, which is mainly used to treat advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer, broke the exclusive monopoly of foreign pharmaceutical giants on similar drugs in China after it entered the market late last year.
As a leading enterprise in China s pharmaceutical industry, Qilu Pharmaceutical realized a sales revenue of 23 billion yuan (about 3.5 billion U.S. dollars) last year. Meanwhile, the company exported 615 million U.S. dollars of products, up 14 percent year on year. ....

United States , Zhao Yan , Zhu Yidong , Li Yan , Qilu Institute Of Innovative Pharmaceutical Research , China Pharmaceutical Enterprises Association , Qilu Pharmaceutical Group Co Ltd , Chinese Foreign Ministry , Shandong Province , Qilu Pharmaceutical , Qilu Institute , Innovative Pharmaceutical , Jiangsu Province , Tan Yong , China Pharmaceutical Enterprises , ஒன்றுபட்டது மாநிலங்களில் , ழோ யான் , லி யான் , சீனா மருந்து நிறுவனங்கள் சங்கம் , சீன வெளிநாட்டு அமைச்சகம் , சாண்டோங் மாகாணம் , புதுமையானது மருந்து , பழுப்பு யோங் , சீனா மருந்து நிறுவனங்கள் ,